MDACC Study No:GOG 0254 ( NCT No: NCT00979992)
Title:A Phase II Evaluation of SU11248 (Sunitinib Malate) IND #74019, NSC# 736511) In The Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
Principal Investigator:Jubilee Brown
Treatment Agent:Sunitinib Malate
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if SU11248 (sunitinib
malate) can help to control clear cell ovarian cancer. The safety of this drug
will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Ovary
Phase of Study:Phase II
Treatment Agents:Sunitinib Malate
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gynecologic Oncology
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jubilee Brown
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-792-1386
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults